Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 7, 2012, Pages 1167-1174

  Lee, Kenneth K C ^a   Wu, David Bin Chia ^b   Chow, Pui Yu ^a   Lee, Vivian Wing Yan ^a   Li, Hong ^c  

^a Prince of Wales Hospital   (Hong Kong)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Chinese; Chronic hepatitis B; Economic; Entecavir; Hepatitis B e antigen negative; Lamivudine

Indexed keywords

ENTECAVIR; LAMIVUDINE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; HEALTH CARE COST; HEPATITIS B; HONG KONG; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; TREATMENT DURATION;

EID: 84862637549     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.07047.x     Document Type: Article

References (27)

1. Lok AS, Lai CL, Wu PC, Wong VC, Yeoh EK, Lin HJ. Hepatitis B virus infection in Chinese families in Hong Kong. Am. J. Epidemiol. 1987; 126: 492-9.
2. Li SC, Ong SC, Lim SG etal. A cost comparison of management of chronic hepatitis B and its associated complications in Hong Kong and Singapore. J. Clin. Gastroenterol. 2004; 38 (Suppl. 3): S136-43.
3. Hong Kong Cancer Registry, Hospital Authority. Hong Kong Cancer Statistics 2003. Cited 20 May 2008. Available from URL:
4. Chen CJ, Yang HI, Su J etal. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
5. Iloeje UH, Yang HI, Su J etal. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-86.
6. Chen G, Lin W, Shen F etal. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am. J. Gastroenterol. 2006; 101: 1797-803.
7. Lok ASF, McMahon BJ. American association for the study of liver diseases practice guidelines: chronic hepatitis B. Hepatology 2007; 45: 507-39.
8. Chang TT, Gish RG, de Man R etal. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2006; 354: 1001-10.
9. Sherman M, Yurdaydin C, Sollano J etal. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130: 2039-49.
10. Leung N, Peng CY, Sollano J etal. Entecavir results in higher HBV DNA reduction vs adefovir in chronically infected HbeAg(+) antiviral-naive adults: 24-week results (E.A.R.L.Y. study). Hepatology 2006; 44 (Suppl. 1): 554A.
11. Lai CL, Shouval D, Lok AS etal. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2006; 354: 1011-20.
12. Yuan Y, Iloeje U, Li H, Hay J, Yao GB. Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese social security program. Value Health 2008; 11 (Suppl. 1): S11-22.
13. Yuan Y, Iloeje UH, Hay J, Saab S. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients. J. Manag. Care Pharm. 2008; 14: 21-33.
14. Veenstra DL, Sullivan SD, Clarke L etal. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. Pharmacoeconomics 2007; 25: 963-77.
15. Kanwal F, Farid M, Martin P etal. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am. J. Gastroenterol. 2006; 101: 2076-89.
16. Yang HI, Iloeje UH, Su J etal. Progression to decompensated cirrhosis in chronic hepatitis B virus infected persons is strongly associated with baseline viral load. J. Hepatol. 2005; 42 (Suppl. 2): 195.
17. Bristol-Myers Squibb Company. Information as supplied by Bristol-Myers Squibb Hong Kong 2009. January, 2010.
18. Pharmacy of Prince of Wales, Hospital authority. Information supplied by Pharmacy Department, Prince of Wales Hospital, Hong Kong Hospital Authority 2009. January, 2010.
19. Lam CL, Levy A, Lozano-Ortega G etal. Valuing health states using utility weights to capture the impact of disease progression in chronic hepatitis B (CHB). ISPOR 2nd Asia-Pacific Conference, Mar 2006, Shanghai, China (Abstract). 2006.
20. Chen CJ, Yang HI, Su J etal. Elevated serum level of hepatitis B virus DNA is an independent risk factor for hepatocellular carcinoma: a long-term follow-up study in Taiwan. J. Hepatol. 2005; 42 (Suppl. 2): 16-7.
21. Tenney DJ, Rose RE, Baldick CJ etal. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5years of therapy. Hepatology 2009; 49: 1503-14.
22. World Health Organization. Macroeconomics and Health: investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. 2001.
23. Census and statistics department, HKSAR. Key Economic and Social Indicators. Cited 1 Dec 2009. Available from URL:
24. Arnold E, Yuan Y, Iloeje U, Cook G. Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B. Appl. Health Econ. Health Policy 2008; 6: 231-46.
25. Liaw YF, Lee CM, Chien RN, Yeh CT. Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis. J. Viral Hepat. 2006; 13: 250-5.
26. Wong GLH, Wong VWS, Choi PCL etal. Evaluation of alanine transaminase and hepatitis B virus DNA to predict liver cirrhosis in hepatitis B e antigen-negative chronic hepatitis B using transient elastography. Am. J. Gastroenterol. 2008; 103: 3071-81.
27. Yao G. Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China. J. Antimicrob. Chemother. 2007; 60: 201-5.